Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment
- PMID: 30642682
- DOI: 10.1016/j.molmed.2018.12.002
Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment
Abstract
The melanocortin-4 receptor (MC4R) - embedded in the leptin-melanocortin pathway - is activated by proopiomelanocortin (POMC)-derived neuropeptides such as α- and β-melanocyte-stimulating hormone (MSH) and plays an important role in hypothalamic body-weight regulation. Accordingly, MC4R is a potential drug target to combat obesity. Previous attempts to develop MC4R agonists failed due to ineffectiveness or severe adverse events. Recently, a new generation of MC4R ligands was developed. Specifically, setmelanotide was found to be effective by inducing biased signalling of the MC4R and thereby reducing feelings of hunger and leading to substantial weight loss in patients with POMC or leptin receptor deficiency. This new potential pharmacological treatment option could be beneficial for further groups of obese patients with defects in the leptin-melanocortin signalling pathway.
Keywords: MC4R; mutation; obesity; signalling; treatment.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.J Clin Endocrinol Metab. 2018 Jul 1;103(7):2601-2612. doi: 10.1210/jc.2018-00258. J Clin Endocrinol Metab. 2018. PMID: 29726959 Free PMC article.
-
Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).Physiol Res. 2020 Sep 30;69(Suppl 2):S245-S254. doi: 10.33549/physiolres.934512. Physiol Res. 2020. PMID: 33094623 Free PMC article. Review.
-
Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.Life Sci. 2022 Oct 15;307:120857. doi: 10.1016/j.lfs.2022.120857. Epub 2022 Aug 2. Life Sci. 2022. PMID: 35931197
-
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8. Mol Metab. 2017. PMID: 29031731 Free PMC article. Clinical Trial.
-
The melanocortin pathway and control of appetite-progress and therapeutic implications.J Endocrinol. 2019 Apr 1;241(1):R1-R33. doi: 10.1530/JOE-18-0596. J Endocrinol. 2019. PMID: 30812013 Free PMC article. Review.
Cited by
-
Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies.Diabetes Obes Metab. 2022 Apr;24(4):583-598. doi: 10.1111/dom.14618. Epub 2022 Jan 11. Diabetes Obes Metab. 2022. PMID: 34882941 Free PMC article. Review.
-
A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.Biomolecules. 2022 Aug 15;12(8):1119. doi: 10.3390/biom12081119. Biomolecules. 2022. PMID: 36009013 Free PMC article.
-
miR-429-3p/LPIN1 Axis Promotes Chicken Abdominal Fat Deposition via PPARγ Pathway.Front Cell Dev Biol. 2020 Dec 21;8:595637. doi: 10.3389/fcell.2020.595637. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33425901 Free PMC article.
-
Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.touchREV Endocrinol. 2024 Oct;20(2):62-71. doi: 10.17925/EE.2024.20.2.9. Epub 2024 Feb 9. touchREV Endocrinol. 2024. PMID: 39526054 Free PMC article. Review.
-
Melanocortin-4 Receptor PLC Activation Is Modulated by an Interaction with the Monocarboxylate Transporter 8.Int J Mol Sci. 2024 Jul 10;25(14):7565. doi: 10.3390/ijms25147565. Int J Mol Sci. 2024. PMID: 39062808 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous